natriuretic-peptide--brain and Pheochromocytoma

Despite adequate presurgical management, blood pressure fluctuations are common during resection of pheochromocytoma or sympathetic paraganglioma (PPGL). To a large extent, the variability in blood pressure control during PPGL resection remains unexplained. Adrenomedullin and B-type natriuretic peptide, measured as MR-proADM and NT-proBNP, respectively, are circulating biomarkers of cardiovascular dysfunction. We investigated whether plasma levels of MR-proADM and NT-proBNP are associated with blood pressure fluctuations during PPGL resection.. Study subjects participated in PRESCRIPT, a randomized controlled trial in patients undergoing PPGL resection. MR-proADM and NT-proBNP were determined in a single plasma sample drawn before surgery. Multivariable linear and logistic regression analyses were used to explore associations between these biomarkers and blood pressure fluctuations, use of vasoconstrictive agents during surgery as well as the occurrence of perioperative cardiovascular events.. A total of 126 PPGL patients were included. Median plasma concentrations of MR-proADM and NT-proBNP were 0.51 (0.41-0.63) nmol/L and 68.7 (27.9-150.4) ng/L, respectively. Neither MR-proADM nor NT-proBNP were associated with blood pressure fluctuations. There was a positive correlation between MR-proADM concentration and the cumulative dose of vasoconstrictive agents (03B2 0.44, P =0.001). Both MR-proADM and NT-proBNP were significantly associated with perioperative cardiovascular events (OR: 5.46, P =0.013 and OR: 1.54, P =0.017, respectively).. plasma MR-proADM or NT-proBNP should not be considered as biomarkers for the presurgical risk assessment of blood pressure fluctuations during PPGL resection. Future studies are needed to explore the potential influence of these biomarkers on the intraoperative requirement of vasoconstrictive agents and the perioperative cardiovascular risk.

Topics: Adrenal Gland Neoplasms; Adrenergic Antagonists; Adrenomedullin; Adult; Aged; Biomarkers; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Female; Follow-Up Studies; Heart Failure; Humans; Intraoperative Complications; Male; Middle Aged; Natriuretic Peptide, Brain; Pheochromocytoma; Prognosis; Risk Assessment; Treatment Outcome

BACKGROUND. Phaeochromocytomas and paragangliomas are rare, mostly benign catecholamine-producing tumours of chromaffin cells of the adrenal medulla or of extra-adrenal paraganglia. Phaeochromocytoma may occur at any age, the greatest frequency being in the fourth and fifth decades. Only on extremely rare occasions does the tumour develop in the very old patients. METHODS. We are describing an 86-year-old patient with phaeochromocytoma, presenting with reversible myocardial dysfunction. RESULTS. This very old patient with phaeochromocytoma had hypertension characterized by labile blood pressure values and increased daytime blood pressure variability. This patient exhibited reversible myocardial dysfunction suggestive for "catecholaminergic cardiomyopathy", as the complication of phaeochromocytoma. After surgical removal of the tumour, recovery of left ventricular function was documented by echocardiography showing normalization of systolic function and improvement of diastolic function. CONCLUSION. Phaeochromocytomas are rare forms of secondary hypertension, but should be considered in the differential diagnosis, regardless of age, even in very old patients.

Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Aged, 80 and over; Blood Pressure; Catecholamines; Diastole; Echocardiography; Follow-Up Studies; Humans; Hypertension; Male; Natriuretic Peptide, Brain; Peptide Fragments; Pheochromocytoma; Poland; Systole; Tomography, X-Ray Computed; Ventricular Dysfunction, Left

The human heart secretes both atrial natriuretic peptide and brain natriuretic peptide. This study attempts to clarify the pathophysiological significance of the peptides in cardiovascular diseases. Using immunoradiometric assay, plasma brain natriuretic peptide and atrial natriuretic peptide levels in essential hypertension, various secondary hypertension, chronic renal failure, chronic heart failure during cardiac pacing, and acute myocardial infarction were determined. Mean plasma brain natriuretic peptide and atrial natriuretic peptide levels in healthy subjects were 3.7 +/- 0.3 and 5.7 +/- 0.3 pmol/L, respectively, and increased as a function of age. Plasma brain natriuretic peptide levels showed a larger increase than atrial natriuretic peptide levels in various cardiovascular diseases. In chronic renal failure, whereas plasma atrial natriuretic peptide levels decreased significantly after hemodialysis and were correlated with the changes in body weight, changes in plasma brain natriuretic peptide levels were less prominent and did not show such a correlation. In chronic heart failure, both basal plasma brain natriuretic peptide and atrial natriuretic peptide levels were also significantly elevated. However, in response to acute ventricular or atrial pacing, brain natriuretic peptide levels did not show any increase in contrast to the marked increase of atrial natriuretic peptide levels. In acute myocardial infarction, brain natriuretic peptide levels showed more prominent changes than atrial natriuretic peptide levels and were correlated with serum levels of creatine kinase and cardiac myosin light chain I in most patients. These results suggest that both brain and atrial natriuretic peptides play an important role in the regulation of cardiovascular homeostasis.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Adrenal Gland Neoplasms; Adult; Aged; Aging; Atrial Natriuretic Factor; Cardiac Pacing, Artificial; Cardiovascular Diseases; Female; Heart Failure; Humans; Hyperaldosteronism; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Pheochromocytoma; Reference Values; Regression Analysis; Renal Dialysis

We demonstrated that a novel natriuretic hormone, brain natriuretic peptide, modestly inhibited the production of cortisol and aldosterone stimulated by ACTH in cultured bovine adrenocortical cells. Moreover, the presence of brain natriuretic peptide was demonstrated in bovine adrenal medulla, suggesting that it may modulate adrenocortical steroidogenesis. Using a specific radioimmunoassay (RIA) for brain natriuretic peptide-26, we confirmed that human cardiac atrial tissues elaborated a considerable amount of brain natriuretic peptide-26-like immunoreactivity (1.00 +/- 0.17 micrograms/g wet weight tissue, n = 3). Its molecular form was similar to that of brain natriuretic peptide-32 and possibly, to gamma-brain natriuretic peptide. However, any immunoreactivity of brain natriuretic peptide could not be detected in human pheochromocytoma tissues and some tissues of the human central nervous system. These observations suggest that brain natriuretic peptide dose not function as a neuropeptide but that it may be a cardiac natriuretic hormone important in human physiology, involved in the balance of water and electrolytes.

Topics: Adrenal Gland Neoplasms; Central Nervous System; Heart Atria; Humans; In Vitro Techniques; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Pheochromocytoma; Radioimmunoassay